NDC Numbers: A New Approach
Author(s): Heckman H Edward
Issue: Sep/Oct 2003 - After the Women's Health Initiative Trial
View All Articles in Issue
Page(s): 358-359
Download in electronic PDF format for $75
Abstract: The author discusses the dilemma of compounding pharmacists involving the use (or lack of use) of National Drug Code numbers in terms of challenges for payment. He suggests a two-pronged strategy to meet this challenge, saying that both strategies must be employed together to successfully eliminate unfair business practices associated with National Drug Code numbers. The first prong of the strategy involves changing the billing methodology of compounds from a drug to a service. The second involves fielding a solid front to stop the current payment practices by third parties and steering them to the new payment paradigm. He concludes that changes in coding claims and a solid pharmacy community united to gain fair treatment will be necessary, and ends with a call to action to pharmacists to unite on this issue.
Related Keywords:
NDC (National Drug Code), National Drug Code
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
NDC Numbers: A New Approach
Heckman H Edward
|
Sep/Oct 2003
Pg. 358-359
|
Quality Control: Bar Codes and Bar Code Scanners for Unit-Dose Medications in a Healthcare Setting
Medi-Dose Inc./EPS Inc.
|
Sep/Oct 2017
Pg. 384-387
|
Optimizing Third-party Reimbursement for Compounded Medications
McElhiney Linda F
|
May/Jun 2013
Pg. 201-204
|
Quality Control: Personal Protective Equipment for Use When Handling Hazardous Drugs
Dillon L R
|
Jan/Feb 2020
Pg. 30-36
|
Gaining Access to Investigational Drug for Treatment: An Investigational New Drug Application Primer
Kramer Mark A, Grilley Bambi J
|
Jul/Aug 2002
Pg. 271-273
|
The Evolution of 21 CFR Parts 210 & 211 for Drug Compounders: An Unspoken Opportunity for Pharmacists
Parks Kenneth Chase, Bernard Brian, Cogdill Christopher Blake
|
Sep/Oct 2015
Pg. 377-380
|
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs
Allen Loyd V Jr
|
Sep/Oct 2017
Pg. 356
|
Setting Up a National System of Compounding Pharmacies: Preventing Error, Assuring Quality, Building Trust
Guedes de Souza Hugo, Favaro Alvaro Jr, Andrade Alba Livia, Gomes Lenir Yago, de Souza Aguiar Simone, do Carmo Garcez Maria
|
Nov/Dec 2009
Pg. 532-536
|
Personalized Medicine and Customized Drug Delivery Systems: The New Trend of Drug Delivery and Disease Management
Soni Abhishek, Gowthamarajan Kuppusamy, Radhakrishnan Arun
|
Mar/Apr 2018
Pg. 108-121
|
Determining Whether a Substance is Legal to Compound with Under Section 503A of the FDCA
Cabaleiro Joe
|
Sep/Oct 2021
Pg. 358-362
|
Does Your Drug Expertise Include Clinical Pharmaceutics?
Newton David W
|
May/Jun 2016
Pg. 202-206
|
PostScription: Drug Disposal: Compounding Pharmacists' Involvement in the Prevention of Prescription Drug Misuse and Abuse
Williams LaVonn A
|
Nov/Dec 2011
Pg. 526-527
|
Specialty Compounding for Improved Patient Care: 2006 National Survey of Compounding Pharmacists
Huffman DC, Holmes Erin R
|
Jan/Feb 2008
Pg. 74-82
|
Disposing of Expired Drugs and Chemicals: New Options for Compounders
Vail Jane
|
Jan/Feb 2008
Pg. 38-47
View Sample |
PostScription: Thousands of Unapproved New Drugs are on the U.S. Market, Part 1
Allen Loyd V Jr
|
Jul/Aug 2007
Pg. 350-351
|
Basics of Compounding for Hazardous Drugs, Part 2: Regulation and Sources of Contamination
Allen Loyd V Jr
|
Nov/Dec 2006
Pg. 446-448
|
Prescription - Pharmacy and the United States Pharmaceopeia-National Formulary - From the Editor
Allen Loyd V Jr
|
May/Jun 2004
Pg. 162
|
Drugs Banned for Use in Food Animals: An Explanation
Davidson Gigi S
|
Mar/Apr 2001
Pg. 101-103
|
PreScription: Discontinued Drugs and Drug Shortages
Allen Loyd V Jr
|
Mar/Apr 2011
Pg. 92
|
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines
Allen Loyd V Jr
|
Jul/Aug 2016
Pg. 351
View Sample |
Return to Top |